Replies to post #250507 on Biotech Values

[DewDiligence]

…Catalent has been acting more like Hospira than Lonza. Not a prime group at this time.

NVO can’t afford to be choosy. They need more production capacity for Wegovy in order to meet demand (#msg-173623535).